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Abbreviations 
AFP – alpha fetoprotein  
HCC – hepatocellular carcinoma  
AASLD – American Association for the Study of Liver Diseases 
NCCN – National Comprehensive Cancer Network  
FIT – fecal immunochemical test   
EMR – electronic medical record  
TACE – transarterial chemoembolization  
HCV – hepatitis C virus 
HBV - hepatitis B virus 
NASH – nonalcoholic steatohepatitis 
AST – aspartate aminotransferase  
ALT – alanine aminotransferase  
INR – international normalized ratio  
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ABSTRACT 
Although surveillance ultrasound and alpha fetoprotein (AFP) have minimal direct harm, 
downstream harms from follow-up tests must be weighed against surveillance benefits when 
determining the value of hepatocellular carcinoma (HCC) screening programs. Our study’s aims 
were to characterize prevalence and correlates of surveillance benefits and harms in cirrhosis 
patients undergoing HCC surveillance. We conducted a retrospective cohort study among 
patients with cirrhosis followed at a safety-net health system between July 2010 and July 2013. 
We recorded surveillance-related benefits, defined as early tumor detection and curative 
treatment, and surveillance-related physical harms, defined as CT or MRI scans, biopsies, or 
other procedures performed for false positive or indeterminate surveillance results. Socio-
demographic and clinical correlates of surveillance harms were evaluated using multivariable 
logistic regression. We identified 680 cirrhosis patients, of whom 78 developed HCC during the 
3-year study period. Of the 48 (61.5%) HCC identified via surveillance, 43.8% were detected by 
ultrasound, 31.2% by AFP, and 25.0% by both surveillance tests.  Surveillance-detected 
patients had a higher proportion of early HCC (70.2% vs. 40.0%, p=0.009), with no difference in 
tumor stage between ultrasound- and AFP-detected tumors (p=0.53). Surveillance-related 
physical harms were observed in 187 (27.5%) patients, with a higher proportion of ultrasound-
related harm than AFP-related harm (22.8% vs. 11.4%, p<0.001). Surveillance-related harms 
were associated with elevated ALT level (OR 1.87, 95%CI 1.26-2.76), thrombocytopenia (OR 
2.06, 95%CI 1.26-3.38), and hepatology subspecialty care (OR 1.63, 95%CI 1.09-2.42).  
Conclusions: Over one-fourth of patients with cirrhosis experience physical harm for false 
positive or indeterminate surveillance tests – more often related to ultrasound than AFP. 
Interventions are needed to reduce surveillance-related harm to increase the value of HCC 
screening programs in clinical practice.  
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INTRODUCTION 
Primary liver cancer is the second leading cause of cancer-related death worldwide and 
the fifth leading cause in the United States.1 The incidence of hepatocellular carcinoma (HCC), 
the most common type of primary liver cancer, is rapidly increasing in the United States, and it 
is projected to become the 3rd leading cause of cancer-related death by 2030.2 The prognosis 
for patients with HCC depends on tumor stage at diagnosis, with curative options only available 
for patients diagnosed at an early stage.3  
Several societies, including the American Association for the Study of Liver Diseases 
(AASLD) and National Comprehensive Cancer Network (NCCN), recommend surveillance using 
ultrasound, with or without alpha fetoprotein (AFP), at six-month intervals in patients with 
cirrhosis.4, 5 Several studies evaluating HCC surveillance among patients with cirrhosis 
demonstrate an association with improved early detection and overall survival but were 
retrospective in design with inherent limitations including lead-time bias, length-time bias, and 
short follow-up duration.6 Notably, these studies only measured HCC surveillance benefits and 
did not characterize potential physical, financial and/or psychological harms.6, 7  
Data for both benefits and harms are needed to determine the value of cancer screening 
programs.8 Experience with other cancer screening programs demonstrates the potential for 
significant physical and financial harms. For example, use of fecal immunochemical test (FIT) in 
colorectal cancer screening has minimal direct harms, but follow-up colonoscopy among those 
with abnormal FIT is associated with risk of perforation, bleeding, and anesthesia 
complications.9, 10 Similarly, HCC surveillance using ultrasound and AFP has minimal discomfort 
and no direct physical harms; however, there are potential “downstream” harms associated with 
diagnostic evaluation protocols. Liver lesions found on ultrasound are typically evaluated with 
CT and/or MRI, which are associated with radiation exposure, contrast injury, and cost.11, 12 If a 
liver lesion cannot be definitively characterized on cross-sectional imaging, patients may 
undergo biopsy, which is associated with risks of bleeding, tumor seeding, and injury to nearby 
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organs.13, 14 Although the imperfect sensitivity (~60-65%) and specificity (~70-95%) of 
surveillance tests and potential for physical harms from these procedures have been 
acknowledged, no study has quantified the frequency or severity of these harms as adverse 
outcomes directly related to HCC surveillance in clinical practice4, 6, 7. Therefore, the aim of our 
study was to characterize prevalence and correlates of HCC surveillance benefits and physical 
harms related to follow-up diagnostic testing in patients with cirrhosis. 
 
METHODS 
Study Population 
We conducted a retrospective cohort study of patients with cirrhosis followed at Parkland 
Health and Hospital System, the safety-net health system for Dallas County. Parkland is an 
integrated health system comprised of twelve primary care provider clinics in low-income 
neighborhoods, a hepatology outpatient clinic, a multidisciplinary HCC clinic, and a tertiary 
hospital – all sharing the same comprehensive electronic medical record (EMR). Parkland 
currently provides inpatient and outpatient care for over 2000 patients with cirrhosis in Dallas. 
Parkland offers a sliding fee scale program, which provides access to primary and subspecialty 
care, including HCC surveillance and diagnostic testing, at low cost for uninsured Dallas County 
residents. 
Patients with cirrhosis were identified by a set of ICD-9 codes, which are highly sensitive 
and specific for cirrhosis (456.0, 456.1, 456.2, 456.21, 567.23, 571.2, 571.5, 572.2, 572.3, and 
572.4)15. One author (O.A.) adjudicated cases to confirm they met diagnostic criteria for 
cirrhosis, defined as stage 4 fibrosis on liver biopsy or a cirrhotic-appearing liver on abdominal 
imaging with signs of portal hypertension (e.g., varices, ascites, splenomegaly). All patients 
were required to have at least one outpatient clinic visit and one HCC surveillance test between 
July 2010 and July 2011 to demonstrate Parkland was their medical home. This study was 
approved by the Institutional Review Board of UT Southwestern Medical Center. 
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Data Collection 
We manually abstracted information on patient demographics, clinical history, laboratory 
data and imaging results from the EMR. All records were reviewed by one investigator (O.A.) 
and independently verified by a second investigator (A.S.). Discrepancies were resolved 
through discussion to establish consensus.  
 
HCC Surveillance Receipt 
Dates of all HCC surveillance tests between July 2010 and July 2013 were abstracted. 
HCC surveillance at Parkland is typically performed using ultrasound, with or without AFP, per 
the AASLD guidelines4 with low use of surveillance CT or MRI. We manually reviewed imaging 
orders, imaging reports, and associated clinical notes to determine intent of ultrasound exams 
and AFP (surveillance vs. diagnostic) and test results. Ultrasounds with indications including 
“surveillance”, “screening”, “rule out HCC”, and “cirrhosis” were classified as surveillance 
exams. Imaging exams performed for diagnostic reasons, e.g. abdominal pain or elevated liver 
enzymes, were classified as non-surveillance cases. We recorded whether ultrasounds were 
normal (no suspicious masses), positive (suspicious liver mass ≥1 cm), or indeterminate (mass 
< 1 cm or unclear if mass is present, e.g. coarse echo-texture). AFP results were considered 
positive if ≥20 ng/mL, the most common cut-off used for HCC surveillance in clinical practice16, 
and indeterminate if ≥11 ng/mL, the upper limit of normal, but < 20 ng/mL.  
 
Benefits of HCC Surveillance 
Benefits of HCC surveillance included: 1) the proportion of HCC patients detected at an 
early tumor stage and 2) proportion of HCC patients eligible for curative treatment. Patients with 
cirrhosis diagnosed with HCC during the study period were identified using ICD-9 codes for 
HCC (155.0) and a prospectively maintained list of all HCC patients seen in the Parkland 
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Multidisciplinary Liver Tumor Clinic.17 All HCC cases were adjudicated to confirm they met 
diagnostic criteria based on AASLD guidelines.4 Tumor characteristics, including tumor nodules, 
maximum diameter, and presence of vascular invasion or distant metastases, were determined 
by imaging studies interpreted by radiologists at our institution, and early stage HCC was 
defined using Milan Criteria, the most common criteria for liver transplantation in the United 
States. Treatment of HCC was categorized as liver transplantation, surgical resection, local 
ablative therapy, transarterial chemoembolization (TACE), systemic chemotherapy, or best 
supportive care. HCC treatment was considered curative if it consisted of liver transplantation, 
surgical resection or local ablative therapy. In patients who received multiple treatments, we 
used a trumping algorithm based on survival benefit (liver transplantation > surgical resection > 
local ablative therapy > TACE > systemic chemotherapy).  
 
Physical Harms of HCC Surveillance 
Using test indication and test results, we identified the subset of patients who had a 
surveillance test that was classified as abnormal. A binary outcome of physical harm was 
defined for each surveillance test result per person. Physical harms included any follow-up tests 
(CT, MRI, liver biopsy, angiogram) performed for false positive or indeterminate surveillance 
results. AASLD and EASL guidelines both recognize the low yield of diagnostic testing and 
recommend short interval repeat ultrasound for indeterminate results; therefore, follow-up tests 
for indeterminate surveillance results (e.g. mass < 1 cm or nodular coarse echo-texture without 
definite mass) were classified as physical harms. We recorded all tests performed for follow-up 
of surveillance results during the study period, so it was possible for patients to have more than 
one follow-up test and physical harm. 
There is variation in clinical significance among measured physical harms. For example, 
a liver biopsy complication is more clinically significant than theoretical radiation harm from a 
single CT scan. To account for different degrees of harm based on exposure to radiation and 
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invasive procedures, we also described surveillance-related harm as an ordinal variable (no 
harm, mild harm, moderate harm, and severe harm). “No harm” was defined as patients without 
any follow-up CT, MRI, or biopsy for positive or indeterminate surveillance tests; “mild harm” as 
those who have a single diagnostic CT or MRI encounter without complications; “moderate 
harm” as those who underwent multiple CT and/or MRI exams; and “severe harm” was defined 
as those who undergo invasive procedures, such as liver biopsy or angiogram, for positive or 
indeterminate tests. 
 
Correlates of Surveillance Harms 
Age, gender, race, and ethnicity were recorded for each patient. Body mass index was 
calculated using height and weight at the index visit and dichotomized (obese vs. non-obese) 
using a cut-off of 30. Data regarding underlying liver disease etiology, presence of 
decompensation (ascites or hepatic encephalopathy), and receipt of hepatology care were 
abstracted from laboratory data and clinical notes. We classified patients according to etiology 
of liver disease, including hepatitis C virus (HCV), hepatitis B virus (HBV), alcohol-related liver 
disease, nonalcoholic steatohepatitis (NASH), and other. HCV infection was defined by the 
presence of a positive HCV antibody, viral load, or genotype. HBV infection was defined by the 
presence of HBV surface antigen or viral load. Patients were determined to have alcohol-related 
cirrhosis if they had a documented history of heavy alcohol use in the clinical notes. Patients 
were classified as NASH if they had evidence of the metabolic syndrome in the absence of HCV 
infection, HBV infection, or a heavy alcohol history. Degree of ascites and hepatic 
encephalopathy was categorized as none, mild or controlled on medications, or 
severe/uncontrolled per clinical notes. Laboratory data of interest from time of index visit 
included platelet count, creatinine, aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), bilirubin, albumin, and international normalized ratio (INR).  
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Statistical Analysis 
We reported point estimates of surveillance-related benefit and physical harms for the 
whole cohort and stratified by surveillance test type (ultrasound vs. AFP), and test result (false 
positive vs. indeterminate). In recognition of the debate concerning whether to use AFP in 
conjunction with ultrasound20, we report stratified estimates by surveillance type (ultrasound vs. 
AFP). Further, the stratified analysis can be informative because ultrasound and AFP may be 
done at different times, with follow-up testing recommended if either surveillance test is positive. 
We estimated the proportion of physical harms by test result (false positive vs. indeterminate) 
because rationale for follow-up testing would likely differ and may require intervention 
strategies. For example, harms due to false positive results may require surveillance tests with 
higher specificity, but harms due to indeterminate results could potentially be minimized by 
provider education to discourage non-guideline concordant care. Multivariable logistic 
regression models were constructed to identify patient-level factors associated with physical 
harm. In a secondary analysis, we performed multivariable ordinal logistic regression to define 
patient-level correlates of harm when defined as a four-level outcome (none, mild, moderate, 
and severe). Final models included covariates significant on univariable analysis and those 
considered clinically important a priori (obesity, cirrhosis etiology, Child Pugh score, hepatology 
care). Statistical significance was defined as p<0.05. All statistical analysis was performed using 
statistical software Stata 11.2 (StataCorp, College Station, TX). 
 
RESULTS 
Patient Characteristics and Receipt of Surveillance 
 A total of 680 patients with cirrhosis met inclusion criteria (Table 1). The mean age of 
patients was 54.3 years, and two-thirds (64.7%) were men. The cohort was racially diverse, 
consisting of 32.5% non-Hispanic Whites, 22.9% Blacks, and 42.1% Hispanic Caucasians. The 
most common etiologies of cirrhosis were HCV infection (56.2%), alcohol-induced liver disease 
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(25.7%), and NASH (11.6%). The median Child Pugh score was 7 (IQR 6-8), with 29.9% of 
patients having Child Pugh A cirrhosis and 57.1% Child Pugh B cirrhosis. Patients were 
followed for a mean of 26.7 ± 11.7 months. At least one surveillance ultrasound had been 
performed in 523 (76.9%) patients, and 640 (94.1%) had ≥1 serum AFP measurement; 
however, only 179 (26.3%) patients had ≥3 surveillance ultrasound exams and only 11 (1.6%) 
had ≥6 surveillance ultrasound exams during the 3-year follow-up period. Overall, 78 (11.5%) 
patients developed HCC during the 3-year study period.  
 
Benefits of HCC Surveillance 
Tumors were detected via surveillance in 48 (61.5%) of the 78 patients who developed 
HCC during the follow-up. Of these, 21 (43.8%) were detected by ultrasound alone, 15 (31.2%) 
by AFP alone, and 12 (25.0%) by both ultrasound and AFP (Figure 1). The remaining 30 HCC 
cases were etected incidentally or presented symptomatically. The majority (70.2%) of HCC 
patients detected by surveillance ultrasound and/or AFP had early HCC, compared to only 
40.0% for those detected symptomatically or incidentally (p=0.009). There was not a significant 
difference in the proportion of HCC within Milan criteria between ultrasound-detected and AFP-
detected tumors (76.2% vs. 66.7%, p=0.53) (Figure 2). Similarly, patients detected via 
surveillance were more likely to undergo curative treatment than non-surveillance detected 
patients (22.9% vs. 0%, p=0.005), with no difference in curative treatment receipt by 
surveillance modality (p=0.43).  
 
Physical Harms of HCC Surveillance 
Physical harms related to false positive or indeterminate surveillance results are shown 
in Table 2 and Figure 1. Of all 680 patients, physical harm was observed in 187 (27.5%) 
patients, with 22 (3.2%) subjected to multiple CT scans, 8 (1.2%) multiple MRI scans, and 36 
(5.3%) a combination of CT and MRI scans. Although most harm was mild to moderate, two 
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patients underwent biopsy of liver lesions (after 2 and 4 MRI exams) and one patient underwent 
an angiogram (after 5 MRI exams). As expected, the proportion of patients experiencing 
physical harm increased with the number of surveillance exams from 11.9% among those with 1 
surveillance exam to 29.6% among those with 2-9 exams to 61.0% among those with ≥10 
surveillance exams.   
There were differences in the proportion of patients experiencing physical harm by 
surveillance modality, with a significantly higher proportion of ultrasound-related physical harm 
than AFP-related harm (p<0.001) (Figure 2). Of the 523 patients with ≥1 surveillance ultrasound, 
ultrasound-related physical harms were observed in 119 (22.8%) patients – 73 with mild harm, 
44 with moderate harm, and 2 with severe harm (both liver biopsies). Diagnostic evaluation was 
triggered by false positive ultrasounds in 63 of these cases, and an additional 56 underwent 
diagnostic evaluation for indeterminate results. Indeterminate results included 35 patients with 
heterogeneous, nodular liver echotexture and 21 patients with subcentimeter liver nodules. 
Among patients with ≥1 serum AFP measurement (n=640), 73 (11.4%) experienced AFP-
related physical harms – 49 with mild harm, 23 with moderate harm, and 1 with severe harm 
(angiogram). Similar to ultrasound, AFP-related harm was due to a combination of false 
positives and indeterminate results. Only 51 patients with AFP-related harm had AFP levels 
exceeding 20 ng/mL, with 22 undergoing diagnostic evaluation for intermediate AFP elevations 
between 11ng/mL and 20 ng/mL. Of note, six of 7 patients with both false positive ultrasound 
and AFP had moderate harm with multiple CT and/or MRI exams performed for diagnostic 
evaluation.  
 
Correlates of Physical Harms 
In univariable analyses, physical harm from false positive or indeterminate surveillance 
results was significantly associated with elevated ALT level, thrombocytopenia, receipt of 
hepatology care, and viral etiology of cirrhosis. In multivariable analysis, physical harm was 
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associated with elevated ALT level (OR 1.87, 95%CI 1.26 – 2.76), thrombocytopenia (OR 2.06, 
95%CI 1.26– 3.38), and receipt of hepatology care (OR 1.63, 95%CI 1.09 – 2.42). A secondary 
analysis evaluating harm as an ordinal outcome similarly found an association with elevated 
ALT (OR 1.92, 95%CI 1.30-2.83), thrombocytopenia (OR 2.18, 95%CI 1.34-3.55), and receipt of 
hepatology care (OR 1.74, 95%CI 1.17-2.57).  
In exploratory subgroup analyses, we evaluated if these associations were driven by 
false positive/indeterminate AFP or ultrasound results. AFP-related harm was associated with 
viral etiology of cirrhosis (OR 5.25, 95%CI 2.31 – 11.92) and elevated ALT (OR 2.84, 95%CI 
1.39 – 5.80), whereas ultrasound-related harm was associated with non-viral etiologies of 
cirrhosis (OR 1.59, 95%CI 1.03 – 2.44) and thrombocytopenia (OR 2.14 95%CI 1.17 – 3.90).  
 
DISCUSSION 
 To the best of our knowledge, our study is one of the first to quantify and weigh physical 
harms of HCC surveillance against HCC early detection in a large cohort of patients with 
cirrhosis. Although HCC surveillance detected over 60% of HCC and nearly doubled early tumor 
detection rates, over one-fourth of patients experienced surveillance harms for false positive or 
indeterminate results and nearly 10% had moderate to severe harm. The prevalence of 
surveillance harms increased steadily over time, increasing from ~10% among those with 1 
surveillance test to >50% among those with 10 or more surveillance exams. Although 
surveillance harms were largely related to false positive ultrasound or AFP results, harms were 
compounded by diagnostic imaging for indeterminate surveillance results, including non-
guideline concordant follow-up for subcentimeter lesions or intermediate AFP elevations.  
 Complementary data regarding benefits and harms are essential to determine the value 
of cancer screening programs.8 Experiences with breast and prostate cancer screening, in 
which evolving data about screening-related harms created controversy about published 
screening guidelines and altered clinical practice, highlights the importance of evaluating 
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screening-related harms in advance of guideline recommendations and widespread use.18 
However, similar to the early evaluations for breast, colon, and prostate cancer screening 
programs, data for HCC surveillance has focused on surveillance-related benefits to date.19 A 
meta-analysis identified nearly 50 studies characterizing the association between HCC 
surveillance and early detection, curative treatment, and overall survival among patients with 
cirrhosis; however, the authors noted a lack of data regarding surveillance-related harms as a 
high priority area for research.7 These data are of particular importance given the benefits of 
HCC surveillance appear to be modest in patients with cirrhosis.6, 20 Our study begins to 
address this need by characterizing physical harms of HCC surveillance.  
 HCC surveillance was responsible for tumor detection in approximately 60% of HCC 
patients and increased early tumor detection rates from 40% to 70%. Tumor detection was 
attributed to ultrasound alone in nearly half of cases, AFP in one-quarter, and both tests in the 
quarter of patients. Early detection and curative treatment receipt did not significantly differ 
between ultrasound and AFP, although this may have been related to small sample size. Similar 
to prior studies20, our data suggest that AFP is complementary to ultrasound and increases the 
effectiveness of HCC surveillance for early tumor detection in clinical practice.  
In terms of surveillance harms, ultrasound and AFP had a similar proportion of false 
positive results; however, the harms of ultrasound were compounded by a high number of 
indeterminate findings, including nodular coarse echotexture that precluded definite exclusion of 
any liver masses and non-guideline concordant management of sub-centimeter lesions. We 
noted radiologists often recommending diagnostic imaging with multi-phase CT or MRI for cases 
with nodular coarse echotexture. Further data and guidance for what constitutes an inadequate 
ultrasound examination is likely needed to help radiologists distinguish cases in which 
ultrasound is sufficient, despite liver nodularity, and cases in which further imaging would be 
beneficial. We also observed high utilization of diagnostic CT and MRI in patients in patients 
with subcentimeter lesions despite guidelines recommending repeat short interval ultrasound  
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given the low risk of HCC. This provider behavior may stem from several causes including lack 
of knowledge about the guidelines, fear of medico-legal liability, hyper-vigilance to find HCC at 
an early stage, and perceived higher positive predictive value for ultrasound than AFP.21, 22 
Many studies have discussed the suboptimal specificity of AFP, resulting in providers using 
clinical judgment when interpreting “low-level” positive AFP values.23, 24 However, there are less 
data discussing false positive results related to ultrasound imaging so providers may place more 
importance on following up any liver lesions, including those that are subcentimeter, given fear 
of potentially missing HCC at an early stage.25 
 Although surveillance-related harms were observed in nearly one-fourth of patients, 
harms were particularly likely in some subsets, including patients receiving hepatology 
subspecialty care, patients with elevated ALT levels, and those with portal hypertension and 
thrombocytopenia.  The association between hepatology care and surveillance harms may be 
mediated by higher provider awareness of HCC risk and a lower threshold for ordering 
diagnostic imaging.26, 27 Prior studies have reported higher rates of false positive AFP in patients 
with viral hepatitis, hepatic inflammation, and elevated liver enzymes.28 Elevated AFP levels 
should be cautiously interpreted in these patients, although AFP-adjusted algorithms or tailoring 
AFP cut-off by liver disease etiology may help reduce rates of unnecessary diagnostic 
imaging.23, 29 Increased liver nodularity in patients with advanced Child Pugh class and 
thrombocytopenia can impair radiologists’ ability to definitively exclude liver lesions, leading to 
recommendations for cross-sectional imaging.30 Alternative surveillance tools for these patients 
are particularly needed given both lower sensitivity and specificity related to poor visualization. 
Although viral etiology was not associated with increased physical harms in multivariable 
analysis, we noted an association with increased AFP-related harm and lower ultrasound-
related harm in exploratory subgroup analyses. As the epidemiology of HCC shifts from HCV-
related to NASH-related, it is possible the proportion of physical harm attributed to ultrasound 
may increase further.  
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Our study adds to the literature highlighting a need for better surveillance tools, with 
improved sensitivity for early tumor detection and improved specificity to avoid unnecessary 
diagnostic tests. Over one-third of HCC cases in our study presented incidentally or 
symptomatically. Suboptimal surveillance tool sensitivity is one of the most common reasons for 
late stage tumor presentation in academic centers, prompting some to adopt CT and MRI as 
surveillance modalities despite a lack of supporting data.21, 31 Our study also highlights the 
potential for physical harms from both ultrasound and AFP, in part related to suboptimal 
surveillance test specificity. Although some may argue the physical harms of CT or MRI imaging 
is minimal, some patients experienced severe harm with biopsy and/or angiogram. Further, 
patients may have also experienced psychological harms while awaiting diagnostic evaluation, 
although this was not measured in our study. Several biomarkers are currently being evaluated, 
but most have yet to undergo phase III or phase IV biomarker studies and may be years 
removed from being fully validated and ready for routine clinical use.32 Further, data evaluating 
any harm related to these biomarkers is also largely unknown. While awaiting newer 
surveillance tools, our study suggests over 40% of surveillance harms is related to non-
guideline concordant management of indeterminate surveillance results, so provider education 
may be a simple intervention reduce surveillance-related harms in the interim.  
Our study had limitations that must be taken into consideration when interpreting the 
results. First, the study was conducted in a single safety-net health system and its results may 
not be generalizable to other health systems. Second, surveillance can result in physical, 
financial, and psychosocial harms but our study was limited to retrospective data available in the 
electronic medical record and therefore focused on physical harms. Further, physical harms 
were largely limited to receipt of diagnostic testing, with less data available to assess 
downstream harms such as contrast-induced renal failure. Third, patients may have potentially 
received HCC surveillance and/or diagnostic tests at outside institutions, although this is unlikely 
because many patients did not have insurance and thus would have to pay out of pocket to get 
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care outside of the safety-net health system in Dallas. Finally, only one-fourth of patients in our 
study had 3 or more surveillance exams during the 3-year study period, and it is possible, if not 
likely, that the magnitude of surveillance benefits and harms would be greater in settings with 
higher surveillance rates. However, the low surveillance rates observed in our study are 
consistent with prior studies.27, 33, 34 Overall, we feel these limitations are outweighed by the 
strengths of the study, particularly given this is the first study to characterize HCC surveillance-
related harms in patients with cirrhosis.    
In summary, HCC surveillance is associated with early tumor detection and increased 
curative treatment receipt; however, these benefits must be weighed against surveillance 
harms. Nearly one-fourth of non-HCC patients underwent diagnostic testing for false positive or 
indeterminate surveillance results and nearly 10% had multiple diagnostic tests. Although false 
positive ultrasound and AFP results were the most common causes, non-guideline concordant 
management of indeterminate ultrasound results accounted for nearly one-third of cases with 
surveillance-related harm. While awaiting more accurate surveillance tools for early tumor 
detection, provider education may help reduce surveillance-related harms and improve the 
value of HCC surveillance in patients with cirrhosis.  
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Figure 1: Flow Diagram of Hepatocellular Carcinoma Surveillance Benefits and Harms in a 
Cohort of Patients with Cirrhosis 
 
 
 
 
 
 
Figure 2: Benefits and Physical Harms of Hepatocellular Carcinoma Surveillance, Stratified by 
Surveillance Modality 
 
 
 
 
There was not a significant difference in the proportion of HCC detected at an early stage by 
surveillance modality (76.2% vs. 66.7% for ultrasound and AFP respectively, p=0.53); however, 
the proportion of patients experiencing ultrasound-related physical harm was significantly higher 
than AFP-related physical harm (22.8% vs. 11.4%, p<0.001).    
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Table 1: Patient socio-demographic and clinical characteristics, overall and stratified by 
occurrence of surveillance-related physical harm 
Characteristic 
All Patients 
(n=680) 
Patients 
without 
Physical Harm 
(n=493) 
Patients with 
Physical 
Harm 
(n=187) 
p-
value* 
Age (years) 54.3 ± 9.4 54.3 ± 9.7 54.3 ± 8.6 0.95 
Sex (% male) 440 (64.7) 316 (64.1) 124 (66.3) 0.59 
Race/Ethnicity 
    Non-Hispanic White 
    Black 
    Hispanic 
    Other/Unknown 
 
221 (32.5) 
156 (22.9) 
286 (42.1) 
17 (2.5) 
 
168 (34.1) 
109 (22.1) 
203 (41.2) 
13 (2.6) 
 
53 (28.4) 
47 (25.1) 
83 (44.4) 
4 (2.1) 
0.49 
Body Mass Index (BMI) 
    BMI  <25 
    BMI 25 – 29.9 
    BMI 30 – 34.9 
    BMI ≥35  
 
166 (24.5) 
225 (33.2) 
158 (23.3) 
129 (19.0) 
 
121 (24.6) 
161 (32.7) 
122 (24.8) 
88 (17.9) 
 
45 (24.2) 
64 (34.4) 
36 (19.4) 
41 (22.0) 
0.38 
Etiology of Liver Disease 
    Hepatitis C 
    Hepatitis B 
    Alcohol-related 
    NASH 
    Other 
 
382 (56.2) 
22 (3.2) 
175 (25.7) 
79 (11.6) 
22 (3.2) 
 
265 (53.7) 
16 (3.3) 
135 (27.4) 
59 (12.0) 
18 (3.6) 
 
117 (62.6) 
6 (3.2) 
40 (21.4) 
20 (10.7) 
4 (2.1) 
0.30 
Child Pugh class 
    Child Pugh A 
    Child Pugh B 
    Child Pugh C 
 
203 (29.8) 
388 (57.1) 
89 (13.1) 
 
148 (30.0) 
282 (57.2) 
63 (12.8) 
 
55 (29.4) 
106 (56.7) 
26 (13.9) 
0.93 
Presence of hepatic 
encephalopathy (%) 
154 (22.7) 110 (22.3) 44 (23.5) 0.74 
Presence of ascites (%) 270 (39.7) 204 (41.4) 66 (35.3) 0.15 
Receipt of hepatology 
care  
441 (65.5) 307 (62.7) 134 (73.2) 0.01 
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Platelet count (* 109/L) 110 ± 64 114 ± 67 103 ± 53 0.06 
Thrombocytopenia 522 (78.0) 362 (74.8) 160 (86.5) 0.001 
Creatinine (mg/dL) 1.0 ± 0.8 1.1 ± 0.9 0.9 ± 0.5 0.02 
AST (U/L) 78 ± 72 73 ± 64 92 ± 89 0.002 
AST > 35 U/L 564 (83.7) 399 (81.9) 165 (88.2) 0.05 
ALT (U/L) 58 ± 50 53 ± 45 73 ± 61 < 0.001 
ALT > 35 U/L 412 (61.0) 277 (56.8) 135 (72.2) 0.001 
Bilirubin (mg/dL) 1.8 ± 2.6 1.9 ± 2.8 1.6 ± 2.1 0.35 
INR 1.3 ± 0.4 1.3 ± 0.5 1.3 ± 0.4 0.65 
Number of HCC 78 (11.5) 63 (12.8) 15 (8.0) 0.08 
 
ALT – alanine aminotransferase; AST – aspartate aminotransferase; HCC – 
hepatocellular carcinoma; INR – international normalized ratio; NASH – nonalcoholic 
steatohepatitis 
* p-value comparing patients with and without any surveillance-related physical harm 
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Table 2: Mild, Moderate, and Severe Physical Harms of Hepatocellular Carcinoma 
Surveillance, Stratified by Surveillance Modality and False Positive vs. Indeterminate 
Result 
Characteristic 
Alpha Fetoprotein 
(n=640) 
Ultrasound  
(n=523) 
False positive Indeterminate  False positive Indeterminate  
Any Harm 51* 22 63* 56 
Mild Harm (n) 
    Single 4-phase CT 
    Single MRI 
 
26 
3 
 
18 
2 
 
32 
6 
 
28 
7 
Moderate Harm (n) 
    Multiple 4-phase CT 
    Multiple MRI 
    4-phase CT and MRI 
 
4 
1 
16 
 
1 
1 
0 
 
7 
5 
11 
 
10 
1 
10 
Severe Harm 
    Biopsy of liver mass (n) 
    Hepatic angiogram (n) 
 
0 
1 
 
0 
0 
 
2 
0 
 
0 
0 
* 7 patients with physical harm related to false positive ultrasound and AFP were 
included in both groups 
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Flow Diagram of Hepatocellular Carcinoma Surveillance Benefits and Harms in a Cohort of Patients with 
Cirrhosis  
Figure 1  
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